| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.neulandlabs.com | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 2,802.18 Cr. | |
| Earnings per share (EPS) | 62.85 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 34.75 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 35.17 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 612.28 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 3.57 | Calculated using Price: 2,184.10 |
| Dividend Yield | 0.23 | Period Ending 2021-03 |
| No. of Shares Subscribed | 1.28 Cr. | 12,829,889 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Named after Father Nieuwland of Notre dame, Neuland Laboratories was incorporated in 1984 by Dr. D. R. Rao for the manufacture of Salbutamol Sulphate, with mere 40 employees. It has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years. Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery. Neuland is a quality conscious, research driven, reliable source of active pharmaceutical ingredients. Operating from India for over two decades, Neuland is the preferred source for the Pharmaceutical Industry across the globe, with strengths in Research based Chemistry and Manufacturing. The Company has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery. Neuland has two world-class API manufacturing facilities close to the city of Hyderabad, capable in handling complex and hazardous reactions. Safety aspects have been given utmost significance may it be plant installation, equipment, systems and personnel to ensure smooth productivity. Dedicated team of manufacturing with incorporation of latest production techniques guarantees delivery of latest intermediate and product to our customers across the globe. Product range of the company includes:
Achievements/ recognition:
|
||
Company Profile
Named after Father Nieuwland of Notre dame, Neuland Laboratories was incorporated in 1984 by Dr. D. R. Rao for the manufacture of Salbutamol Sulphate, with mere 40 employees.
It has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.
Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery. Neuland is a quality conscious, research driven, reliable source of active pharmaceutical ingredients.
Operating from India for over two decades, Neuland is the preferred source for the Pharmaceutical Industry across the globe, with strengths in Research based Chemistry and Manufacturing.
The Company has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery.
Neuland has two world-class API manufacturing facilities close to the city of Hyderabad, capable in handling complex and hazardous reactions. Safety aspects have been given utmost significance may it be plant installation, equipment, systems and personnel to ensure smooth productivity. Dedicated team of manufacturing with incorporation of latest production techniques guarantees delivery of latest intermediate and product to our customers across the globe.
Product range of the company includes:
Achievements/ recognition:
| 1 Day |
|
+2.25% |
| 1 Week |
|
-1.53% |
| 1 Month |
|
+7.45% |
| 3 Month |
|
-13.93% |
| 6 Month |
|
+59.59% |
| 1 Year |
|
+219.43% |
| 2 Year |
|
+328.09% |
| 5 Year |
|
+125.43% |
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 15.92 | 24.14 | 11.24 | 15.64 | 22.34 | 5.02 | 3.48 | 2.30 | 10.79 | |
| Return on Capital Employed (%) | 15.58 | 18.99 | 15.75 | 18.57 | 15.98 | 4.07 | 3.99 | 7.85 | 12.81 | |
| Return on Assets (%) | 3.26 | 5.89 | 3.20 | 5.23 | 6.65 | 1.23 | 1.49 | 1.37 | 6.31 |
| Particulars | 9 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Shh. Funds | 100 | 124 | 161 | 187 | 546 | 558 | 699 | 710 | 786 | |
| Non Curr. Liab. | 62 | 52 | 55 | 69 | 54 | 146 | 104 | 163 | 170 | |
| Curr. Liab. | 263 | 307 | 295 | 268 | 286 | 367 | 327 | 358 | 369 | |
| Minority Int. | 0 | 0 | 0 | |||||||
| Equity & Liab. | 425 | 483 | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | |
| Non Curr. Assets | 198 | 196 | 196 | 210 | 511 | 624 | 677 | 716 | 775 | |
| Curr. Assets | 227 | 288 | 316 | 314 | 375 | 447 | 453 | 515 | 550 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 425 | 483 | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 |
| Particulars | 9 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Net Sales | 461 | 466 | 469 | 510 | 579 | 527 | 667 | 763 | 937 | |
| Other Income | 4 | 3 | 1 | 2 | 1 | 5 | 3 | 4 | 16 | |
| Total Income | 465 | 469 | 470 | 512 | 580 | 532 | 670 | 767 | 953 | |
| Total Expenditure | -403 | -395 | -403 | -430 | -473 | -477 | -608 | -661 | -790 | |
| PBIDT | 62 | 74 | 67 | 82 | 108 | 55 | 62 | 106 | 163 | |
| Interest | -31 | -25 | -27 | -24 | -21 | -19 | -16 | -22 | -18 | |
| Depreciation | -15 | -15 | -15 | -16 | -19 | -22 | -26 | -31 | -40 | |
| Taxation | -2 | -8 | -9 | -15 | -20 | -2 | -4 | -37 | -25 | |
| Exceptional Items | ||||||||||
| PAT | 14 | 27 | 16 | 27 | 47 | 12 | 16 | 16 | 81 |
| Particulars | 9 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 26 | 49 | 13 | 45 | 39 | 11 | 70 | 57 | 189 | |
| Cash Fr. Inv. | -7 | -10 | -14 | -20 | -42 | -116 | -77 | -49 | -84 | |
| Cash Fr. Finan. | -20 | -39 | 1 | -24 | 0 | 105 | 12 | -5 | -114 | |
| Net Change | -1 | 0 | 0 | 1 | -4 | 0 | 5 | 3 | -9 | |
| Cash & Cash Eqvt | 1 | 1 | 1 | 2 | 3 | 3 | 8 | 11 | 2 |
|
Fri, 16 Jul 2021
Board Meeting Intimation for Considering And Approving The Unaudited Financial Results For The Quarter Ended June 30 2021 NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2021 inter alia to consider and approve the Unaudited Financial Results for the quarter ended June 30 2021. |
|
Mon, 12 Jul 2021
Shareholding for the Period Ended June 30 2021 Neuland Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here |
|
Thu, 08 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 |
| Fri, 23 Jul 2021 |
Stock Underperforming Benchmark Index in both 1 Week and 3 Month
|
Stock Underperforming Sectoral Index in both 1 Week and 3 Month
|
Strongly Underperforming Benchmark index
|
Strongly Underperforming Sectoral index
|
Both SRS And ARS Above Zero
|
Equities
M.F.
Sectors